NLS Pharma News

Biotech article – September 29, 2026

Beyond manufacturing: Stockholm turns to multiomics to improve cell and gene therapies

Stockholm-Uppsala has built substantial clinical, research, and manufacturing capabilities around advanced therapies. Bringing those strengths closer to the region’s expertise in proteomics, genomics, and other molecular technologies could help answer the next questions in cell and gene therapy: why treatments work, why they fail, and how more patients can benefit.

ProBio and Curocell Reach Major CAR‑T Commercialization Milestone

Bringing next-generation therapies to patients requires more than manufacturing capacity. It demands a CDMO with proven regulatory, technical, and commercial execution.

Pharma Business – October 8, 2026

Bavarian Nordic raises 2026 guidance to DKK 6.1 billion on US rabies vaccine demand

Bavarian Nordic has raised its full-year 2026 guidance for the third time this year. It now expects revenue of about DKK 6,100 million, up from about DKK 5,700 million, driven by higher sales of rabies vaccines, mainly in the US.

Pharma Business – October 8, 2026

Prime Minister to open Thor Medical’s AlphaOne plant

Norwegian Prime Minister Jonas Gahr Støre will officially open Thor Medical’s AlphaOne production facility at Herøya Industrial Park on October 19. The Oslo-based company supplies high-purity alpha-emitting isotopes to the radiopharmaceutical industry.

Biotech Business – October 6, 2026

Alvotech expands manufacturing capacity for US biosimilar supply

Icelandic biosimilar developer Alvotech has signed a long-term manufacturing agreement with LOTTE Biologics for US-based production. A day earlier, the FDA approved a second production suite in Reykjavik for its Humira biosimilar SIMLANDI.

Clinical Trials

Clinical Trials – October 7, 2026

Pharmability doses first patient with TIR-C

Stockholm-based Pharmability has dosed the first patient in its Phase Ib study of TIR-C in atopic dermatitis, and the first cohort is now fully enrolled. The trial is the first in which the drug candidate is tested in humans.

Clinical Trials – October 7, 2026

Epcoritamab meets Phase III goal in frontline lymphoma

Genmab and AbbVie’s bispecific antibody epcoritamab, added to standard R-CHOP chemoimmunotherapy, significantly improved progression-free survival in the Phase III EPCORE DLBCL-2 trial in newly diagnosed diffuse large B-cell lymphoma (DLBCL). The companies say it is the first Phase III study of a bispecific antibody combination to show such a benefit in the frontline setting.

Clinical Trials – October 6, 2026

Survodutide meets Phase III goals in diabetes

Boehringer Ingelheim’s survodutide, licensed from Danish Zealand Pharma, met both co-primary endpoints in the Phase III SYNCHRONIZE-2 trial in people with obesity or overweight and type 2 diabetes, with weight loss of up to 13.1% after 76 weeks versus 3.1% on placebo.

Clinical Trials – October 6, 2026

Tarek Samad on the next test for Lundbeck’s Parkinson’s drug

Lundbeck has randomized the first patient in the Phase II DARE2 trial of its oral Parkinson’s candidate Lu AF28996. In an interview with NLS, Tarek Samad, Head of R&D, explains what the trial needs to show to justify Phase III and where the drug could fit alongside existing treatments.

Clinical Trials – October 3, 2026

Genmab reports Rina-S Phase 2 data

Genmab has reported Phase 2 results for its antibody-drug conjugate rinatabart sesutecan (Rina-S) in platinum-resistant ovarian cancer, with a confirmed objective response rate of 45.9% among 109 treated patients.

Clinical Trials – October 3, 2026

Lundbeck reports Phase IV Vyepti data

Lundbeck has reported headline results from the Phase IV THRIVE trial, in which 60% of migraine patients who had responded inadequately to a prior CGRP-targeting preventive therapy reported being “much” or “very much” improved after 24 weeks on Vyepti (eptinezumab).

Clinical Trials – October 2, 2026

Mendus presents five-year vididencel data

Stockholm-based Mendus has presented updated five-year follow-up data from its completed ADVANCE II trial in acute myeloid leukemia (AML). It also gave an update on the ongoing VITAL-CML trial of its immunotherapy vididencel in chronic myeloid leukemia (CML). The data were presented at the Second Bologna Workshop on Immunotherapy for AML in Italy.

Biotech article – October 1, 2026

Anocca doses first patient in Sweden

Södertälje-based Anocca has dosed the first patient in Sweden with its TCR-T cell therapy, which targets KRAS G12V mutations in pancreatic cancer. Sweden is the third European country where a patient has received the therapy.

Clinical Trials – October 1, 2026

Atrogi reports positive muscle data

Stockholm-based Atrogi has reported positive human data for ATR-258, its first-in-class oral therapy designed to improve muscle function and body composition. Over eight weeks, treatment was associated with an approximately 13% improvement in lower-extremity muscle power, together with more lean mass and less fat mass.

Clinical Trials – September 29, 2026

Cinclus Pharma completes patient visits in Phase III study

All planned patient visits have now been completed in the company’s Phase III HEEALING1 study of linaprazan glurate in erosive GERD. Topline results are still expected in Q4 2026.

Profiles in Pharma

Profiles in Pharma – April 2, 2025

The Jalkanens: A shared thirst for knowledge

For Sirpa and Markku Jalkanen of Finland, M.D. and Ph.D., married, immunotherapy researchers, working together came as naturally as a courtship.

Profiles in Pharma – November 1, 2023

Jonina Gudmundsdottir, Coripharma

In the heart of Iceland’s life sciences industry, Jonina Gudmundsdottir, the CEO of Coripharma, is making her mark. With a deep understanding of the industry’s challenges and a relentless drive for excellence, Gudmundsdottir has steered Coripharma toward transformative success. Iceland’s life sciences industry has thrived in recent years, propelled by its unique strengths. With a […]

Profiles in Pharma – July 3, 2023

Deborah Dunsire

The CEO of Lundbeck, who announced that she will retire last week, did not initially intend to join the life science industry, but it captivated her more than 30 years ago, and the ability to transform lives still drives her to this day. For more than 100 years, Lundbeck has been at the forefront of […]

Profiles in Pharma – October 1, 2021

Malin Parkler – Passionate about science, health & leadership

Malin Parkler, CEO of Pfizer Sweden, is driven by curiosity and a passion to build knowledge and evolve the life science industry – with the ultimate goal to yield real benefits for patients. Rarely has the world been more in need of leaders. As the global community struggled with the COVID-19 pandemic last year, people […]

Profiles in Pharma – August 15, 2019

Katarina Ageborg, CEO AstraZeneca Sweden

Few companies are as synonymous with Sweden as AstraZeneca and few CEOs as visible. Yet, Katarina Ageborg, AstraZeneca Sweden’s new CEO, prefers not to think about being center stage, but instead about what her position can do for the company, Sweden and the pharmaceutical industry as a whole. “I don’t think about it that way […]

Profiles in Pharma – July 1, 2017

Embracing diversity – for the sake of true innovation

Bahija Jallal’s curiosity and passion for science have been strong driving forces throughout her entire career, as has her belief in the need for diversity to truly bring forth innovation. A view that is also deeply incorporated in her job as Head of MedImmune. Editor’s note: In 2019 Bahika Jallal left MedImmune and became the […]

Profiles in Pharma – March 22, 2017

“The scientist in me wants to make a difference”

After ten years of diabetes research and development at Novo Nordisk, Dorte X. Gram took her findings and work further to start something on her own. As founder and CEO of PILA PHARMA she hopes to bring a new oral anti-diabetic agent to the market.

Profiles in Pharma – March 8, 2017

“We have to embrace the new era of diabetes care”

Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer at Novo Nordisk, talks about the Danish pharma giant’s drug-development strategy, the new era of diabetes care and his 25 year-long passion for his job. The changing diabetes market, with increasing competition and high prices for diabetes products in the US, has made the world’s […]

Profiles in Pharma – February 16, 2017

From regulator to pharma industry specialist

Dr. Thomas Lönngren, former head of the EMA and today a pharmaceutical consultant, provides some insights on the aftermath of Brexit, describes current challenges the industry is facing and takes a short walk down memory lane on his career journey. The summer of 2016 will be remembered for many things; record temperatures, terrorist acts in […]

Profiles in Pharma – April 21, 2014

Jan Lundberg: The long view of R&D at Eli Lilly

Like sports, R&D requires team spirit, commitment, and a long view says Dr. Jan Lundberg, Lilly executive vice president for science and technology, and president of Lilly Research Laboratories. Dr. Jan Lundberg’s online bios and YouTube videos portray a steely pharmaceutical executive whose idea of fun is a 90 km ski race. It’s all true. […]